Consumer-First Obesity Care: Reimagining the Patient-Pharma Relationship

The obesity care landscape is undergoing a fundamental transformation as breakthrough GLP-1 therapies and digital health solutions create new opportunities for patient-centered care models. Traditional pharmaceutical-provider-patient relationships are being challenged by direct-to-consumer approaches, personalized treatment protocols, and integrated care platforms that prioritize patient experience and long-term engagement over traditional clinical workflows.

This shift toward consumer-first obesity care is reshaping how pharmaceutical companies, healthcare providers, and digital health platforms interact with patients throughout their weight management journey. The challenge lies in creating seamless, patient-centric experiences that integrate advanced therapeutics with behavioral support, lifestyle interventions, and ongoing care coordination while navigating complex regulatory, reimbursement, and clinical safety requirements.

Join us to discuss:

• How are innovative obesity care models prioritizing patient experience and engagement while maintaining clinical safety and therapeutic effectiveness?
• What direct-to-consumer and hybrid care approaches are proving most successful in supporting long-term patient outcomes and treatment adherence in obesity management?
• How are pharmaceutical companies, healthcare providers, and digital health platforms reimagining their roles and relationships to create more patient-centered obesity care experiences?